{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:47:26Z","timestamp":1788173246348,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA104509"],"award-info":[{"award-number":["R01CA104509"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA009523"],"award-info":[{"award-number":["CA009523"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA023100"],"award-info":[{"award-number":["P30CA023100"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100107","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:12:48Z","timestamp":1745583168000},"page":"100107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting HASPIN kinase disrupts SR protein\u2013mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML"],"prefix":"10.1016","volume":"2","author":[{"given":"Mengdan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4356-7480","authenticated-orcid":false,"given":"Amanda G.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Stoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2541-6443","authenticated-orcid":false,"given":"Dong-Er","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib1","first-page":"12","article-title":"Cancer statistics, 2024 [published correction appears in CA Cancer J Clin. 2024;74(2):203]","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.bneo.2025.100107_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bneo.2025.100107_bib3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.bneo.2025.100107_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/leu.2014.179","article-title":"Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1\/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors","volume":"29","author":"Wichmann","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2025.100107_bib6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction [published correction appears in Cell. 2009;138(4):807]","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bneo.2025.100107_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ncponc0558","article-title":"Mechanisms of disease: oncogene addiction--a rationale for molecular targeting in cancer therapy","volume":"3","author":"Weinstein","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100107_bib8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/leu.2016.209","article-title":"Protein kinase CK2 regulates AKT, NF-kappaB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia","volume":"31","author":"Quotti Tubi","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccell.2019.12.002","article-title":"Vitamin B6 addiction in acute myeloid leukemia","volume":"37","author":"Chen","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bneo.2025.100107_bib10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.molcel.2018.02.011","article-title":"LKB1, salt-inducible kinases, and MEF2C are linked dependencies in acute myeloid leukemia","volume":"69","author":"Tarumoto","year":"2018","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.bneo.2025.100107_bib11","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100107_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design [published correction appears in Nat Rev Drug Discov. 2021;20(10):798]","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.bneo.2025.100107_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1186\/s12885-022-09622-0","article-title":"Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies","volume":"22","author":"Platzbecker","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.bneo.2025.100107_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000877","article-title":"Palbociclib in acute leukemias with KMT2A-rearrangement: results of AMLSG 23-14 trial","volume":"7","author":"Gaidzik","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.bneo.2025.100107_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bneo.2025.100107_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.bneo.2025.100107_bib18","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1-2","key":"10.1016\/j.bneo.2025.100107_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bneo.2025.100107_bib21","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cell.2017.01.013","article-title":"Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras","volume":"168","author":"Wang","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bneo.2025.100107_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nbt.3235","article-title":"Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains","volume":"33","author":"Shi","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100107_bib23","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3390\/molecules26071981","article-title":"Aurora kinase B inhibition: a potential therapeutic strategy for cancer","volume":"26","author":"Borah","year":"2021","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bneo.2025.100107_bib24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4161\/cc.4.5.1683","article-title":"Haspin: a mitotic histone kinase required for metaphase chromosome alignment","volume":"4","author":"Dai","year":"2005","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.bneo.2025.100107_bib25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1101\/gad.1267105","article-title":"The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment","volume":"19","author":"Dai","year":"2005","journal-title":"Genes Dev"},{"issue":"10","key":"10.1016\/j.bneo.2025.100107_bib26","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.18632\/aging.103005","article-title":"GSG2 (Haspin) promotes development and progression of bladder cancer through targeting KIF15 (kinase-12)","volume":"12","author":"Chen","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"10.1016\/j.bneo.2025.100107_bib27","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8042","article-title":"GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration","volume":"45","author":"Zhou","year":"2021","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib28","first-page":"139","article-title":"Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo","volume":"57","author":"Yu","year":"2020","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bneo.2025.100107_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12059","article-title":"Essential role of autoactivation circuitry on Aurora B-mediated H2AX-pS121 in mitosis","volume":"7","author":"Shimada","year":"2016","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.bneo.2025.100107_bib30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00018-022-04507-8","article-title":"Global phosphoproteomic analysis identified key kinases regulating male meiosis in mouse","volume":"79","author":"Li","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"10.1016\/j.bneo.2025.100107_bib31","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/onc.2011.335","article-title":"Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin","volume":"31","author":"Huertas","year":"2012","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bneo.2025.100107_bib32","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1002\/jcp.29328","article-title":"Haspin inhibition delays cell cycle progression through interphase in cancer cells","volume":"235","author":"Wang","year":"2020","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100107_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00412-009-0250-4","article-title":"Haspin: a newly discovered regulator of mitotic chromosome behavior","volume":"119","author":"Higgins","year":"2010","journal-title":"Chromosoma"},{"issue":"10","key":"10.1016\/j.bneo.2025.100107_bib34","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100099R","article-title":"Loss of Haspin suppresses cancer cell proliferation by interfering with cell cycle progression at multiple stages","volume":"35","author":"Wang","year":"2021","journal-title":"FASEB J"},{"issue":"7","key":"10.1016\/j.bneo.2025.100107_bib35","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1074\/mcp.M113.034819","article-title":"Modulation of the chromatin phosphoproteome by the Haspin protein kinase","volume":"13","author":"Maiolica","year":"2014","journal-title":"Mol Cell Proteomics"},{"issue":"7945","key":"10.1016\/j.bneo.2025.100107_bib36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41586-022-05575-3","article-title":"An atlas of substrate specificities for the human serine\/threonine kinome","volume":"613","author":"Johnson","year":"2023","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bneo.2025.100107_bib37","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrg3778","article-title":"Context-dependent control of alternative splicing by RNA-binding proteins","volume":"15","author":"Fu","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib38","article-title":"Phosphorylation-mediated regulation of alternative splicing in cancer","volume":"2013","author":"Naro","year":"2013","journal-title":"Int J Cell Biol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100107_bib39","first-page":"604","article-title":"Regulation of pre-mRNA splicing: indispensable role of post-translational modifications of splicing factors","volume":"13","author":"Kretova","year":"2023","journal-title":"Life (Basel)"},{"issue":"3","key":"10.1016\/j.bneo.2025.100107_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00412-013-0407-z","article-title":"Regulation of splicing by SR proteins and SR protein-specific kinases","volume":"122","author":"Zhou","year":"2013","journal-title":"Chromosoma"},{"issue":"20","key":"10.1016\/j.bneo.2025.100107_bib41","doi-asserted-by":"crossref","first-page":"8233","DOI":"10.1073\/pnas.1017700108","article-title":"Interaction between the RNA binding domains of Ser-Arg splicing factor 1 and U1-70K snRNP protein determines early spliceosome assembly","volume":"108","author":"Cho","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.bneo.2025.100107_bib42","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1128\/MCB.19.10.6991","article-title":"The protein kinase Clk\/Sty directly modulates SR protein activity: both hyper- and hypophosphorylation inhibit splicing","volume":"19","author":"Prasad","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100107_bib43","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nsmb.1485","article-title":"Phosphorylation switches the general splicing repressor SRp38 to a sequence-specific activator","volume":"15","author":"Feng","year":"2008","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100107_bib44","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1073\/pnas.94.4.1148","article-title":"Sequence-specific RNA binding by an SR protein requires RS domain phosphorylation: creation of an SRp40-specific splicing enhancer","volume":"94","author":"Tacke","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6482","key":"10.1016\/j.bneo.2025.100107_bib45","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/369678a0","article-title":"A serine kinase regulates intracellular localization of splicing factors in the cell cycle","volume":"369","author":"Gui","year":"1994","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bneo.2025.100107_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/j.1460-2075.1996.tb00357.x","article-title":"The Clk\/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution","volume":"15","author":"Colwill","year":"1996","journal-title":"EMBO J"},{"issue":"27","key":"10.1016\/j.bneo.2025.100107_bib47","doi-asserted-by":"crossref","first-page":"23058","DOI":"10.18632\/oncotarget.5492","article-title":"Regulation of Bim in health and disease","volume":"6","author":"Sionov","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ"},{"issue":"22","key":"10.1016\/j.bneo.2025.100107_bib49","first-page":"2059","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia [published correction appears in N Engl J Med. 2013;369(1):98]","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bneo.2025.100107_bib50","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bneo.2025.100107_bib51","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"63","key":"10.1016\/j.bneo.2025.100107_bib52","doi-asserted-by":"crossref","first-page":"107206","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","author":"Bogenberger","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bneo.2025.100107_bib53","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"issue":"48","key":"10.1016\/j.bneo.2025.100107_bib54","doi-asserted-by":"crossref","first-page":"20204","DOI":"10.1073\/pnas.0908485106","article-title":"Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization","volume":"106","author":"Villa","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"10.1016\/j.bneo.2025.100107_bib55","doi-asserted-by":"crossref","first-page":"20198","DOI":"10.1073\/pnas.0901989106","article-title":"Structure and functional characterization of the atypical human kinase haspin","volume":"106","author":"Eswaran","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bneo.2025.100107_bib56","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10288","article-title":"An extensive program of periodic alternative splicing linked to cell cycle progression","volume":"5","author":"Dominguez","year":"2016","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.bneo.2025.100107_bib57","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1006\/bbrc.1998.9247","article-title":"cdc2 kinase-mediated phosphorylation of splicing factor SF2\/ASF","volume":"249","author":"Okamoto","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.bneo.2025.100107_bib58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2011.03.014","article-title":"SON controls cell-cycle progression by coordinated regulation of RNA splicing","volume":"42","author":"Ahn","year":"2011","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.bneo.2025.100107_bib59","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/nar\/gkx1255","article-title":"PolyC-binding proteins enhance expression of the CDK2 cell cycle regulatory protein via alternative splicing","volume":"46","author":"Ji","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.bneo.2025.100107_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.117","article-title":"Depletion of pre-mRNA splicing factor Cdc5L inhibits mitotic progression and triggers mitotic catastrophe","volume":"5","author":"Mu","year":"2014","journal-title":"Cell Death Dis"},{"issue":"22","key":"10.1016\/j.bneo.2025.100107_bib61","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood-2018-10-839985","article-title":"RNA-binding proteins in hematopoiesis and hematological malignancy","volume":"133","author":"Hodson","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100107_bib62","article-title":"Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells","volume":"4","author":"van der Werf","year":"2023","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.bneo.2025.100107_bib63","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.stem.2016.08.003","article-title":"RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML","volume":"19","author":"Crews","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib64","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1038\/s41467-018-07620-0","article-title":"SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4","volume":"9","author":"Tzelepis","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bneo.2025.100107_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00125","article-title":"Differential roles of PML isoforms","volume":"3","author":"Nisole","year":"2013","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100107_bib66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12185-014-1518-x","article-title":"The role of PML in hematopoietic and leukemic stem cell maintenance","volume":"100","author":"Nakahara","year":"2014","journal-title":"Int J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100107_bib67","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood-2022-162773","article-title":"The serine\/threonine kinase HASPIN is a novel dependency in t(8;21) AML","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100107_bib68","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1039\/D3MD00192J","article-title":"Dual FLT3\/haspin kinase inhibitor based on 3H-pyrazolo[4,3-f]quinoline scaffold with activities against acute myeloid leukemia","volume":"14","author":"Kempen","year":"2023","journal-title":"RSC Med Chem"},{"issue":"15","key":"10.1016\/j.bneo.2025.100107_bib69","doi-asserted-by":"crossref","first-page":"12711","DOI":"10.1021\/acs.jmedchem.4c00718","article-title":"A comprehensive in vitro characterization of a new class of indole-based compounds developed as selective Haspin inhibitors","volume":"67","author":"Vestuto","year":"2024","journal-title":"J Med Chem"},{"issue":"13","key":"10.1016\/j.bneo.2025.100107_bib70","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1080\/10428194.2024.2390574","article-title":"Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study","volume":"65","author":"Pelland","year":"2024","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:11:03Z","timestamp":1756127463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2950328025000421"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100107","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting HASPIN kinase disrupts SR protein\u2013mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100107"}}